Roger Perlmutter, Eikon Therapeutics CEO

Roger Perl­mut­ter builds Eikon's pipeline with deal-mak­ing flur­ry, rais­ing $106M more

Eikon Ther­a­peu­tics an­nounced three busi­ness de­vel­op­ment deals on Thurs­day, ef­fec­tive­ly drop­ping in a pipeline of can­cer drugs along­side more than $100 mil­lion in fresh fund­ing.

The Hay­ward, CA-based com­pa­ny has be­come one of biotech’s rich­est star­tups since its 2019 found­ing, hav­ing raised near­ly $775 mil­lion. It’s de­vel­op­ing a mas­sive, au­to­mat­ed re­search ap­proach built around No­bel Prize-win­ning mi­cro­scope sci­ence to peer in­side cells and watch pro­teins in ac­tion. Af­ter its Se­ries B last year, Pitch­Book re­port­ed a $3.02 bil­lion val­u­a­tion. And while CEO Roger Perl­mut­ter de­clined to com­ment on that fig­ure, he said its first tranche of near­ly $106 mil­lion in Se­ries C fund­ing is a “mean­ing­ful step-up to our Se­ries B val­u­a­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.